Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.20.

A number of analysts have recently issued reports on STOK shares. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright decreased their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $11.63 on Monday. The company has a market capitalization of $635.00 million, a P/E ratio of 14.72 and a beta of 1.09. The company's 50 day moving average price is $10.22 and its two-hundred day moving average price is $9.56. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $16.15.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the transaction, the insider now directly owns 25,782 shares of the company's stock, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Siren L.L.C. boosted its position in Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after purchasing an additional 247,347 shares during the period. Jane Street Group LLC boosted its position in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock valued at $179,000 after acquiring an additional 15,001 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock valued at $11,053,000 after acquiring an additional 293,072 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after acquiring an additional 1,149 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Stoke Therapeutics in the first quarter valued at about $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.